Grifols SA (GRFS)
7.005
+0.06
(+0.94%)
USD |
NASDAQ |
May 10, 16:00
7.005
0.00 (0.00%)
After-Hours: 18:04
Grifols Price to Book Value: 0.7386 for May 10, 2024
Price to Book Value Chart
Historical Price to Book Value Data
Date | Value |
---|---|
May 09, 2024 | 0.7317 |
May 08, 2024 | 0.7211 |
May 07, 2024 | 0.7169 |
May 06, 2024 | 0.7401 |
May 03, 2024 | 0.6927 |
May 02, 2024 | 0.6737 |
May 01, 2024 | 0.7159 |
April 30, 2024 | 0.6779 |
April 29, 2024 | 0.6832 |
April 26, 2024 | 0.6726 |
April 25, 2024 | 0.661 |
April 24, 2024 | 0.6737 |
April 23, 2024 | 0.6832 |
April 22, 2024 | 0.6642 |
April 19, 2024 | 0.6621 |
April 18, 2024 | 0.6895 |
April 17, 2024 | 0.6937 |
April 16, 2024 | 0.7148 |
April 15, 2024 | 0.6895 |
April 12, 2024 | 0.6916 |
April 11, 2024 | 0.7011 |
April 10, 2024 | 0.7348 |
April 09, 2024 | 0.757 |
April 08, 2024 | 0.7686 |
April 05, 2024 | 0.7475 |
Date | Value |
---|---|
April 04, 2024 | 0.7232 |
April 03, 2024 | 0.7264 |
April 02, 2024 | 0.7148 |
April 01, 2024 | 0.7043 |
March 28, 2024 | 0.7043 |
March 27, 2024 | 0.7011 |
March 26, 2024 | 0.6832 |
March 25, 2024 | 0.6705 |
March 22, 2024 | 0.6558 |
March 21, 2024 | 0.7148 |
March 20, 2024 | 0.6631 |
March 19, 2024 | 0.6389 |
March 18, 2024 | 0.6378 |
March 15, 2024 | 0.6463 |
March 14, 2024 | 0.6073 |
March 13, 2024 | 0.6684 |
March 12, 2024 | 0.6631 |
March 11, 2024 | 0.7137 |
March 08, 2024 | 0.738 |
March 07, 2024 | 0.5914 |
March 06, 2024 | 0.5767 |
March 05, 2024 | 0.6505 |
March 04, 2024 | 0.699 |
March 01, 2024 | 0.7443 |
February 29, 2024 | 0.7918 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.5767
Minimum
Mar 06 2024
3.246
Maximum
Feb 21 2020
1.616
Average
1.446
Median
Oct 29 2021
Price to Book Value Benchmarks
DBV Technologies SA | 0.7930 |
Adaptimmune Therapeutics PLC | 6.996 |
Akari Therapeutics PLC | -- |
Biodexa Pharmaceuticals Plc | 0.6842 |
NuCana PLC | 0.3935 |
Price to Book Value Related Metrics
PE Ratio | 22.52 |
PS Ratio | 0.6595 |
Price | 7.005 |
Earnings Yield | 4.44% |
Market Cap | 4.757B |
Operating PE Ratio | 5.917 |
Normalized PE Ratio | 32.86 |